Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
Taylan GurgenciJanet HardyGeorgie HuggettKaryn FosterAnita PelecanosRistan GreerJennifer PhilipAlison HaywoodRuwani MendisPatsy YatesPhillip GoodPublished in: Trials (2024)
ANZCTR ACTRN12622000083796 . Protocol number 001/20. Registered on 21 January 2022. Recruitment started on 8 August 2022.